300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Cryptocurrency
Retail
Social Impact
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Legal
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
eSports
Construction
Infrastructure
Cannabis
LGBT
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Celebrity
Climate
Music
Art
Real Estate
Sporting Goods
Publishing
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Canada
Germany
India
United Kingdom
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Olivier Ossipoff

Chairman @ Xerys

Paris, France

Olivier Ossipoff is a venture - series unknown investor at Xerys in Paris focused on Health Care and Biotechnology. Olivier Ossipoff - Chairman @ Xerys

Total investments:
7
Last investment:
Lead investor:
100%

Last updated:

Industries Olivier Ossipoff invests in

Health CareBiotechnologyMedicalBiopharmaRecycling

Stages Olivier Ossipoff invests in

Venture - Series UnknownSeries BFunding Round

Countries Olivier Ossipoff invests in

FranceUnited States

Investment Focus

Industry

  • Health Care 2 (29%)
  • Biotechnology 2 (29%)
  • Medical 1 (14%)
  • Biopharma 1 (14%)
  • Recycling 1 (14%)
See all 11 industries →

Stage

  • Venture - Series Unknown 3 (43%)
  • Series B 1 (14%)
  • Funding Round 1 (14%)

Country

  • France 3 (43%)
  • United States 1 (14%)

Investments

CompanyDescriptionRoundLinks
Advanced BioDesign Advanced BioDesign
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. $15.6M / Venture - Series Unknown / Feb 02, 2023
Biolog-id Biolog-id
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. $25M / Venture - Series Unknown / May 05, 2022
Skytech Skytech
Skytech provides innovative solutions and unique recovery services for plastics for the benefit of manufacturers. Skytech gives plastics a second life. It has developed TRIBLAST, an innovative and patented process for recycling polymers based on triboelectricity. It contributes to the development of the circular economy. $6.1M / Venture - Series Unknown / Jan 13, 2021
Advanced BioDesign Advanced BioDesign
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. $9.8M / Venture - Series Unknown / Feb 25, 2020
Biolog-id Biolog-id
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. $32.9M / Nov 19, 2019
Alzprotect Alzprotect
AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). $15.4M / Series B / Jan 22, 2018
Biolog-id Biolog-id
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id.
Xerys

About Xerys

VC Fund · Paris, France

Xery is a portfolio management Company specializing in Venture Capital - Biotech, Medtech, Cleantech, Technology

Xerys Contacts

NameEmailPhoneSocials
Jacques Simonnet Chairman of the supervisory board
Olivier Ossipoff Chairman

Sign up to unlock verified contacts

Unlock Contacts

3 more contacts available

Open Xerys full profile

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Cryptocurrency
Retail
Social Impact
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Legal
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
eSports
Construction
Infrastructure
Cannabis
LGBT
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Celebrity
Climate
Music
Art
Real Estate
Sporting Goods
Publishing
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Burkina Faso
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Canada
Germany
India
United Kingdom
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Argentina
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Olivier Ossipoff invest in?

Olivier Ossipoff invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Olivier Ossipoff last invest?

The most recent investment recorded for Olivier Ossipoff closed in Feb 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Olivier Ossipoff Find email